RenovoRx (RNXT) Expected to Post Earnings on Thursday

RenovoRx (NASDAQ:RNXT) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect RenovoRx to announce earnings of ($0.05) per share and revenue of $1.06 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. The business had revenue of $0.91 million during the quarter, compared to analyst estimates of $0.70 million. RenovoRx had a negative net margin of 621.71% and a negative return on equity of 135.11%. On average, analysts expect RenovoRx to post ($0.24) EPS for the current fiscal year and ($0.12) EPS for the next fiscal year.

RenovoRx Price Performance

Shares of RNXT stock traded up $0.04 on Tuesday, hitting $1.29. 180,795 shares of the stock traded hands, compared to its average volume of 457,114. The firm has a market cap of $58.44 million, a price-to-earnings ratio of -4.17 and a beta of 0.98. RenovoRx has a 52 week low of $0.70 and a 52 week high of $2.59. The firm has a 50 day simple moving average of $1.56 and a two-hundred day simple moving average of $1.11.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RNXT shares. Wall Street Zen raised shares of RenovoRx from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings raised RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company’s approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.

RenovoRx’s lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.